NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice

NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice

Background: The pathogenesis of sepsis-associated encephalopathy (SAE) is complicated, while the efficacy of current treatment technologies is poor. Therefore, the discovery of related targets and the development of new drugs are essential.Methods: A mouse model of SAE was constructed by intraperito...

Full description

Bibliographic Details
Main Authors: Lu Chen, Wenxiang Qing, Zexiong Yi, Guoxin Lin, Qianyi Peng, Fan Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Nutrition
Subjects:
NU9056
gut microbiota
NLRP3 inflammasome
derivative metabolites
sepsis-associated encephalopathy
Online Access:https://www.frontiersin.org/articles/10.3389/fnut.2021.701760/full

Internet

https://www.frontiersin.org/articles/10.3389/fnut.2021.701760/full

Similar Items